HOME >> BIOLOGY >> NEWS
Researchers shed light on mechanism of action used by anti-cancer drug

RICHMOND, Va. (June 11, 2007) Virginia Commonwealth University Massey Cancer Center researchers have uncovered a new mechanism of action of the anti-cancer drug sorafenib, which could stimulate the development of novel regimens in which it is combined with other molecularly targeted agents for patients with blood cancers and solid tumors.

In the new study, led by Steven Grant, M.D., Masseys associate director for translational research and co-leader of the cancer centers cancer cell biology program, VCU researchers identified a mechanism by which sorafenib inhibits protein translation, and which may be involved in reducing expression of pro-survival factors, such as Mcl-1, and other proteins. The findings were published online in the journal Molecular and Cellular Biology on June 4.

According to Grant, sorafenib, or Nexavar which is manufactured by Bayer Pharmaceuticals, has recently been approved for the treatment of patients with renal cell cancer, the most common form of kidney cancer in adults. It was originally developed as an inhibitor of the oncogene, Raf, which is frequently mutated in numerous cancers, including leukemia. Oncogenes are typically responsible for promoting tumor growth.

Previous findings by Grants team, reported in the Journal of Biologic Chemistry, showed that in human leukemia cells, sorafenib lethality was less a consequence of Raf inhibition, but rather reflected interference with the synthesis of Mcl-1. They found that sorafenib interfered with Mcl-1 translation, a process in which proteins are synthesized from their constituent amino acids. However, the mechanism by which protein translation was inhibited by sorafenib remained largely unknown.

In the present work, Grant and his team found that in human leukemia cells, sorafenib induces a process known as endoplasmic reticulum (ER) stress, which results from accumulation of misfolded proteins in the ER. The ER is a subcellular structure which
'"/>

Contact: Sathya Achia-Abraham
sbachia@vcu.edu
804-827-0890
Virginia Commonwealth University
11-Jun-2007


Page: 1 2

Related biology news :

1. Researchers find pathway that controls cell size and division
2. Researchers watch antibiotics, bacteria meet at atomic level
3. Researchers discover gene responsible for Restless Legs Syndrome
4. Researchers witness natural selection at work in dramatic comeback of male butterflies
5. Researchers discover human embryonic stem cells are the ultimate perpetual fuel cell
6. Researchers use new approach to predict protein function
7. Researchers probe risks, benefits of folic acid fortification
8. Researchers identify genetic mutation that may alter tumor cell proliferation
9. Researchers discover method for identifying how cancer evades the immune system
10. Researchers use adult stem cells to create soft tissue
11. Researchers find gene that spurs development of the epididymis

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/13/2020)... , ... March 13, 2020 , ... ... with Vivorte Inc. to be the exclusive distributor of the Louisville-based company’s orthobiologics ... and medical education expertise to distribute Vivorte’s calcium phosphate-based bone allograft (Trabexus) and ...
(Date:3/11/2020)... ... March 11, 2020 , ... ... sensing, today announced smart human body temperature infrared touch-free monitoring product family, a ... meter WxS x800-IRTM, supporting flexible wireless uplink for cloud connectivity such as NB-IoT, ...
(Date:3/9/2020)... DALLAS (PRWEB) , ... March ... ... by enterprises witnessed a steep growth rate of 64% last year, as ... to new research from Everest Group. Unfortunately, only 13% of all transformation ...
Breaking Biology News(10 mins):
(Date:3/10/2020)... ... March 10, 2020 , ... Ortho Clinical Diagnostics, a global leader of in ... ORTHOTM Sera, ID-MTS, a suite of extended antigen in a gel testing format used ... ORTHO VISION® and ORTHO VISION® Max in the United States and Canada. The clearances ...
(Date:3/3/2020)... ... March 03, 2020 , ... ... biotech and medical device industries, was recognized by INC. 5,000 on an annual ... lists to note industry leaders greatly impacting their spheres of influence and experiencing ...
(Date:2/21/2020)... ... 2020 , ... In a free session on Tuesday, March 10, ... Lisa Dilworth, BS, MS, Vice President Rare, Orphan and Pediatric Diseases, and Rachael Young, ... to support patients, sites and sponsors. , When planning a rare disease clinical trial, ...
(Date:2/19/2020)... ... February 18, 2020 , ... Shoreline Biome, a ... strain level, recently unveiled a novel DNA isolation product. , Shoreline Rapid Prep ... high molecular weight (HMW) single-stranded DNA (ssDNA) in excess of 40 kB from ...
Breaking Biology Technology:
Cached News: